T1	Participants 78 106	prescription opioid abusers.
T2	Participants 516 626	89 PO-dependent adults screened for a trial evaluating the relative efficacy of buprenorphine taper durations.
T3	Participants 854 918	participants reporting lifetime heroin use â‰¥5 (H(+); n=41) vs.
T4	Participants 919 940	<5 (H(-); n=48) times
T5	Participants 1785 1813	treatment-seeking PO abusers
